Literature DB >> 15452750

Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.

Janne Martikainen1, Hannu Valtonen, Tuula Pirttilä.   

Abstract

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease characterized by a progressive deterioration in cognitive functions. AD will have a major impact on public health in the coming decades. The objective of this study was to evaluate the potential cost-effectiveness of a cognitive-behavioral family intervention (CBFI) program in patients with mild Alzheimer's disease in Finland. A second-order Monte Carlo technique was used to simulate the effectiveness of the intervention in AD patients and their informal caregivers over the course of 5 years. A Bayesian approach was applied to answer the question: how likely is it that the CBFI program is cost-effective? Based on existing information, the incremental net health benefit of the CBFI program is positive with over 0.9 probability, which indicates that the CBFI program has the highest probability of being optimal by providing greater net benefits than current practice. Furthermore, changes in the health-related quality of life of the caregivers were insensitive to AD patients' disease stage and settings of care. From the methodological point of view, the acceptability curve with a Bayesian approach provides a flexible way to characterize uncertainty surrounding cost-effectiveness parameters.

Entities:  

Mesh:

Year:  2004        PMID: 15452750     DOI: 10.1007/s10198-003-0214-1

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  34 in total

1.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Authors:  H Feldman; S Gauthier; J Hecker; B Vellas; P Subbiah; E Whalen
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

3.  Evaluation of the costs of caring for the senile demented elderly: a pilot study.

Authors:  T W Hu; L F Huang; W S Cartwright
Journal:  Gerontologist       Date:  1986-04

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.

Authors:  P J Neumann; S S Araki; A Arcelus; A Longo; G Papadopoulos; K S Kosik; K M Kuntz; A Bhattacharjya
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

6.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

7.  Caregiving as a risk factor for mortality: the Caregiver Health Effects Study.

Authors:  R Schulz; S R Beach
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

8.  Effects of supporting community-living demented patients and their caregivers: a randomized trial.

Authors:  U Eloniemi-Sulkava; I L Notkola; M Hentinen; S L Kivelä; J Sivenius; R Sulkava
Journal:  J Am Geriatr Soc       Date:  2001-10       Impact factor: 5.562

9.  Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study.

Authors:  D L Bachman; P A Wolf; R Linn; J E Knoefel; J Cobb; A Belanger; R B D'Agostino; L R White
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

Review 10.  Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention.

Authors:  J J Dunkin; C Anderson-Hanley
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  10 in total

Review 1.  Dementia case management effectiveness on health care costs and resource utilization: a systematic review of randomized controlled trials.

Authors:  C Pimouguet; T Lavaud; J F Dartigues; C Helmer
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  Cost-Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review.

Authors:  Wilfried Guets; Hareth Al-Janabi; Lionel Perrier
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

Review 3.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

4.  Do nurse-led skill training interventions affect informal caregivers' out-of-pocket expenditures?

Authors:  Courtney Harold Van Houtven; Joshua M Thorpe; Deborah Chestnutt; Margory Molloy; John C Boling; Linda Lindsey Davis
Journal:  Gerontologist       Date:  2012-03-28

5.  Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.

Authors:  Pei-Jung Lin; Brittany D'Cruz; Ashley A Leech; Peter J Neumann; Myrlene Sanon Aigbogun; Dorothee Oberdhan; Tara A Lavelle
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

6.  Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.

Authors:  F Nourhashémi; M G Olde Rikkert; A Burns; B Winblad; G B Frisoni; J Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

Review 7.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

8.  (Cost)-effectiveness of case-management by district nurses among primary informal caregivers of older adults with dementia symptoms and the older adults who receive informal care: design of a randomized controlled trial [ISCRTN83135728].

Authors:  Aaltje P D Jansen; Hein P J van Hout; Harm W J van Marwijk; Giel Nijpels; Martine C de Bruijne; Judith E Bosmans; Anne-Margriet Pot; Wim A B Stalman
Journal:  BMC Public Health       Date:  2005-12-12       Impact factor: 3.295

9.  Private costs almost equal health care costs when intervening in mild Alzheimer's: a cohort study alongside the DAISY trial.

Authors:  Rikke Søgaard; Jan Sørensen; Frans B Waldorff; Ane Eckermann; Dorthe V Buss; Gunhild Waldemar
Journal:  BMC Health Serv Res       Date:  2009-11-25       Impact factor: 2.655

10.  Early psychosocial intervention in Alzheimer's disease: cost utility evaluation alongside the Danish Alzheimer's Intervention Study (DAISY).

Authors:  Rikke Søgaard; Jan Sørensen; Frans B Waldorff; Ane Eckermann; Dorte V Buss; Kieu T T Phung; Gunhild Waldemar
Journal:  BMJ Open       Date:  2014-01-15       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.